clinical trial · NCT05173012
Study to Evaluate SAGE-324 in Participants With Essential Tremor
Essential TremorSAGE-324SAGE-324 Matched Placebo
brief summary
The primary purpose of this study is to evaluate the dose-response relationship of different doses of SAGE-324 on upper extremity tremor in participants with essential tremor (ET) in the monotherapy cohort.
started
Jan 5, 2022
primary completion
May 2, 2024
completion
May 16, 2024
last updated
May 16, 2025
official title
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol